Join our Hosts Professor Craig Underhill and Rachael Babin to discuss the June 2026 PBS update including a new listing for fixed-duration acalabrutinib plus venetoclax in chronic lymphocytic leukaemia.
They also explore the growing challenges facing Australia's PBS, with special guest Professor John Zalcberg AO sharing his insights into delays in access to innovative cancer medicines, global pricing pressures, the impact of changing US drug policy and what reforms may be needed to ensure Australian patients continue to benefit from timely access to life-changing treatments.
Follow PBS Update for regular discussions on PBS listings and oncology policy changes affecting Australian healthcare professionals.
Visit the Show Notes for links to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Oncology Network. Innehållet i podden är skapat av The Oncology Network och inte av,
eller tillsammans med, Poddtoppen.
